Stock QNRX QUOIN PHARMACEUTICALS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Real-time Estimate Cboe BZX
Other stock markets
 10:08:57 2024-05-03 am EDT 		5-day change 1st Jan Change
0.745 USD +2.05% Intraday chart for Quoin Pharmaceuticals, Ltd. +16.08% -84.91%
Mar. 15 Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating MT
Mar. 14 Quoin Pharmaceuticals Seeks M&A Opportunities CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
AQ
Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating
MT
Quoin Pharmaceuticals Seeks M&A Opportunities
CI
Transcript : Quoin Pharmaceuticals, Ltd., Q4 2023 Earnings Call, Mar 14, 2024
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
AQ
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
AQ
ADRs Close Higher; Dada Nexus Ltd. Climbs 30%
DJ
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%
DJ
Top Midday Decliners
MT
Quoin Pharmaceuticals Prices $6.5 Million Public Offering; Shares Fall
MT
Top Premarket Decliners
MT
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
AQ
Top Midday Gainers
MT
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial
DJ
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
AQ
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
CI
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
AQ
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
AQ
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. QNRX Stock
  4. News Quoin Pharmaceuticals, Ltd.